Download PDFPDF
Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Dementia in parkinson disease: need of clarification

    Dear Editor,

    I have read with great interest the article by Edison et al about the amyloid load in patients with Parkinson´s disease (PD), PD with dementia (PDD) and dementia with Lewy bodies (DLB) (1). Authors hypothesised that amyloid pathology would be uncommon in PD without dementia, an occasional feature of PDD and present in the majority of DLB cases. This hypothesis was clearly demonstrated (1). However,...

    Show More
    Conflict of Interest:
    None declared.